Screening performance of abbreviated versions of the UPSIT smell test.


Journal

Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161

Informations de publication

Date de publication:
Aug 2019
Historique:
received: 13 02 2019
accepted: 23 04 2019
revised: 17 04 2019
pubmed: 6 5 2019
medline: 10 1 2020
entrez: 5 5 2019
Statut: ppublish

Résumé

Hyposmia can develop with age and in neurodegenerative conditions, including Parkinson's disease (PD). The University of Pennsylvania Smell Identification Test (UPSIT) is a 40-item smell test widely used for assessing hyposmia. However, in a number of situations, such as identifying hyposmic individuals in large populations, shorter tests are preferable. We assessed the ability of shorter UPSIT subsets to detect hyposmia in 891 healthy participants from the PREDICT-PD study. Shorter subsets included Versions A and B of the 4-item Pocket Smell Test (PST) and 12-item Brief Smell Identification Test (BSIT). Using a data-driven approach, we evaluated screening performances of 23,231,378 combinations of 1-7 smell items from the full UPSIT to derive "winning" subsets, and validated findings separately in another 191 healthy individuals. We then compared discriminatory UPSIT smells between PREDICT-PD participants and 40 PD patients, and assessed the performance of "winning" subsets containing discriminatory smells in PD patients. PST Versions A and B achieved sensitivity/specificity of 76.8%/64.9% and 86.6%/45.9%, respectively, while BSIT Versions A and B achieved 83.1%/79.5% and 96.5%/51.8%. From the data-driven analysis, 2 "winning" 7-item subsets surpassed the screening performance of 12-item BSITs (validation sensitivity/specificity of 88.2%/85.4% and 100%/53.5%), while a "winning" 4-item subset had higher sensitivity than PST-A, -B, and even BSIT-A (validation sensitivity 91.2%). Interestingly, several discriminatory smells featured within "winning" subsets, and demonstrated high-screening performances for identifying hyposmic PD patients. Using abbreviated smell tests could provide a cost-effective means of large-scale hyposmia screening, allowing more targeted UPSIT administration in general and PD-related settings.

Sections du résumé

BACKGROUND BACKGROUND
Hyposmia can develop with age and in neurodegenerative conditions, including Parkinson's disease (PD). The University of Pennsylvania Smell Identification Test (UPSIT) is a 40-item smell test widely used for assessing hyposmia. However, in a number of situations, such as identifying hyposmic individuals in large populations, shorter tests are preferable.
METHODS METHODS
We assessed the ability of shorter UPSIT subsets to detect hyposmia in 891 healthy participants from the PREDICT-PD study. Shorter subsets included Versions A and B of the 4-item Pocket Smell Test (PST) and 12-item Brief Smell Identification Test (BSIT). Using a data-driven approach, we evaluated screening performances of 23,231,378 combinations of 1-7 smell items from the full UPSIT to derive "winning" subsets, and validated findings separately in another 191 healthy individuals. We then compared discriminatory UPSIT smells between PREDICT-PD participants and 40 PD patients, and assessed the performance of "winning" subsets containing discriminatory smells in PD patients.
RESULTS RESULTS
PST Versions A and B achieved sensitivity/specificity of 76.8%/64.9% and 86.6%/45.9%, respectively, while BSIT Versions A and B achieved 83.1%/79.5% and 96.5%/51.8%. From the data-driven analysis, 2 "winning" 7-item subsets surpassed the screening performance of 12-item BSITs (validation sensitivity/specificity of 88.2%/85.4% and 100%/53.5%), while a "winning" 4-item subset had higher sensitivity than PST-A, -B, and even BSIT-A (validation sensitivity 91.2%). Interestingly, several discriminatory smells featured within "winning" subsets, and demonstrated high-screening performances for identifying hyposmic PD patients.
CONCLUSION CONCLUSIONS
Using abbreviated smell tests could provide a cost-effective means of large-scale hyposmia screening, allowing more targeted UPSIT administration in general and PD-related settings.

Identifiants

pubmed: 31053960
doi: 10.1007/s00415-019-09340-x
pii: 10.1007/s00415-019-09340-x
pmc: PMC6647236
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1897-1906

Subventions

Organisme : Parkinson's UK
ID : F-1201
Pays : United Kingdom
Organisme : Parkinson's UK
ID : G-1606
Pays : United Kingdom

Références

Physiol Behav. 1984 Mar;32(3):489-502
pubmed: 6463130
Mov Disord. 2012 Mar;27(3):406-12
pubmed: 22237833
Mov Disord. 2007 Apr 30;22(6):839-42
pubmed: 17357143
Ann Clin Transl Neurol. 2017 Sep 08;4(10):714-721
pubmed: 29046880
Mov Disord. 2017 Feb;32(2):219-226
pubmed: 28090684
Expert Rev Neurother. 2009 Dec;9(12):1773-9
pubmed: 19951136
J Neurol Neurosurg Psychiatry. 1997 May;62(5):436-46
pubmed: 9153598
Lancet. 1992 Jul 18;340(8812):186
pubmed: 1352606
J Neurol. 2013 Dec;260(12):3158-60
pubmed: 24158272
Laryngoscope. 1984 Feb;94(2 Pt 1):176-8
pubmed: 6694486
J Neurol Neurosurg Psychiatry. 2014 Jan;85(1):31-7
pubmed: 23828833
Ann Neurol. 2005 Jul;58(1):155-60
pubmed: 15984022
Chem Senses. 2003 Nov;28(9):799-805
pubmed: 14654448
Arch Neurol. 2003 Apr;60(4):545-9
pubmed: 12707068
Neurosci Bull. 2017 Oct;33(5):515-525
pubmed: 28831680
JAMA. 2002 Nov 13;288(18):2307-12
pubmed: 12425708
J Neurol. 2007 Jan;254(1):84-90
pubmed: 17508142
Acta Neuropathol. 2014 Apr;127(4):459-75
pubmed: 24554308
NPJ Parkinsons Dis. 2018 Jan 15;4:2
pubmed: 29354684
Int Rev Neurobiol. 2017;134:1493-1505
pubmed: 28805581
Chemosens Percept. 2015 Sep;8(3):138-148
pubmed: 27833669
Nat Rev Neurol. 2012 May 15;8(6):329-39
pubmed: 22584158
Neurology. 1988 Aug;38(8):1237-44
pubmed: 3399075
Parkinsonism Relat Disord. 2009 Aug;15(7):490-4
pubmed: 19138875
Lancet Neurol. 2015 Oct;14(10):1002-9
pubmed: 26271532
Neurobiol Dis. 2012 Jun;46(3):527-52
pubmed: 22192366
J Neuropathol Exp Neurol. 2002 May;61(5):413-26
pubmed: 12030260
Biomark Med. 2010 Oct;4(5):661-70
pubmed: 20945979
Acta Neuropathol. 2009 Jun;117(6):613-34
pubmed: 19399512
Ann N Y Acad Sci. 1989;561:76-86
pubmed: 2525363
Ann Neurol. 2008 Feb;63(2):167-73
pubmed: 18067173
Mov Disord. 2012 Apr 15;27(5):656-65
pubmed: 22508284
Laryngoscope. 1996 Mar;106(3 Pt 1):353-6
pubmed: 8614203

Auteurs

Theresita Joseph (T)

University College London Medical School, London, UK.

Stephen D Auger (SD)

Preventive Neurology Unit, Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, EC1M 6BQ, UK.

Luisa Peress (L)

Barts and The London School of Medicine and Dentistry, London, UK.

Daniel Rack (D)

Barts and The London School of Medicine and Dentistry, London, UK.

Jack Cuzick (J)

Preventive Neurology Unit, Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, EC1M 6BQ, UK.

Gavin Giovannoni (G)

Preventive Neurology Unit, Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, EC1M 6BQ, UK.
Blizard Institute, Barts and the London Queen Mary University of London, London, UK.

Andrew Lees (A)

Reta Lila Weston Institute, Department of Clinical and Movement Neurosciences, UCL Institute of Neurology, London, UK.

Anette E Schrag (AE)

Department of Clinical and Movement Neurosciences, UCL Institute of Neurology, London, UK.

Alastair J Noyce (AJ)

Preventive Neurology Unit, Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, EC1M 6BQ, UK. a.noyce@qmul.ac.uk.
Reta Lila Weston Institute, Department of Clinical and Movement Neurosciences, UCL Institute of Neurology, London, UK. a.noyce@qmul.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH